Literature DB >> 9588689

Morphine analgesia in the formalin test: reversal by microinjection of quaternary naloxone into the posterior hypothalamic area or periaqueductal gray.

B H Manning1, K B Franklin.   

Abstract

Bilateral microinjection of 5 nmol morphine into the posterior hypothalamic area (PHA), periaqueductal gray matter (PAG) or ventral tegmental area (VTA) elicits powerful suppression of nociceptive behaviors in the formalin test, an animal model of injury produced pain. The object of the present study was to determine whether analgesia in the formalin test (50 microl 2.5% formalin injected s.c. in one hindpaw) induced by systemically administered morphine requires opioid action at these sites, or other putative sites of opioid action. Morphine sulphate (6 mg/kg s.c.) produced almost complete analgesia in the second phase of the formalin test (30-50 min after formalin). Bilateral microinjection of the quaternary opioid antagonist naloxone methobromide (NxBr, 28 ng in 0.5 microl, 22 min after morphine) into the PHA completely abolished morphine analgesia, while NxBr into PAG partially reversed analgesia. Microinjection of NxBr into the VTA, central nucleus of the amygdala, habenula, striatum, nucleus accumbens or hypothalamic sites outside the PHA did not antagonize morphine analgesia, although microinjections into some of these sites appeared to reduce the cataleptogenic effects of morphine. The data indicate that the PHA and PAG are probably the primary sites of action of morphine in the formalin test.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9588689     DOI: 10.1016/s0166-4328(97)00130-7

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  13 in total

1.  Mapping of reinforcing and analgesic effects of the mu opioid agonist endomorphin-1 in the ventral midbrain of the rat.

Authors:  Thomas C Jhou; Sheng-Ping Xu; Mary R Lee; Courtney L Gallen; Satoshi Ikemoto
Journal:  Psychopharmacology (Berl)       Date:  2012-06-06       Impact factor: 4.530

2.  PAG mu opioid receptor activation underlies sex differences in morphine antinociception.

Authors:  Scott A Bernal; Michael M Morgan; Rebecca M Craft
Journal:  Behav Brain Res       Date:  2006-11-21       Impact factor: 3.332

3.  A lateralized deficit in morphine antinociception after unilateral inactivation of the central amygdala.

Authors:  B H Manning
Journal:  J Neurosci       Date:  1998-11-15       Impact factor: 6.167

4.  Functional magnetic resonance imaging studies of opioid receptor-mediated modulation of noxious-evoked BOLD contrast in rats.

Authors:  Y B Shah; L Haynes; M J W Prior; C A Marsden; P G Morris; V Chapman
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

5.  Dopamine reuptake inhibition in the rostral agranular insular cortex produces antinociception.

Authors:  A R Burkey; E Carstens; L Jasmin
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

6.  Reduction in opioid- and cannabinoid-induced antinociception in rhesus monkeys after bilateral lesions of the amygdaloid complex.

Authors:  B H Manning; N M Merin; I D Meng; D G Amaral
Journal:  J Neurosci       Date:  2001-10-15       Impact factor: 6.167

7.  The posterior hypothalamus exerts opposing effects on nociception via the A7 catecholamine cell group in rats.

Authors:  Y Jeong; J R Moes; M Wagner; J E Holden
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

8.  The role of spinal orexin-1 receptors in posterior hypothalamic modulation of neuropathic pain.

Authors:  Y Jeong; J E Holden
Journal:  Neuroscience       Date:  2009-02-11       Impact factor: 3.590

9.  Posterior hypothalamic modulation of light-evoked trigeminal neural activity and lacrimation.

Authors:  A Katagiri; K Okamoto; R Thompson; D A Bereiter
Journal:  Neuroscience       Date:  2013-04-30       Impact factor: 3.590

10.  Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain.

Authors:  Fani Pantouli; Travis W Grim; Cullen L Schmid; Agnes Acevedo-Canabal; Nicole M Kennedy; Michael D Cameron; Thomas D Bannister; Laura M Bohn
Journal:  Neuropharmacology       Date:  2020-12-17       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.